MARKET

CALA

CALA

Calithera Biosciences Inc
EXMKT
0.020
0.000
0.00%
Closed 14:21 05/23 EDT
OPEN
0.020
PREV CLOSE
0.020
HIGH
0.020
LOW
0.020
VOLUME
10.00K
TURNOVER
200
52 WEEK HIGH
13.38
52 WEEK LOW
0.013
MARKET CAP
97.45K
P/E (TTM)
-0.0044
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CALA last week (0513-0517)?
Weekly Report · 3d ago
Weekly Report: what happened at CALA last week (0506-0510)?
Weekly Report · 05/13 10:18
Weekly Report: what happened at CALA last week (0429-0503)?
Weekly Report · 05/06 10:22
Weekly Report: what happened at CALA last week (0422-0426)?
Weekly Report · 04/29 10:26
Weekly Report: what happened at CALA last week (0415-0419)?
Weekly Report · 04/22 10:20
Weekly Report: what happened at CALA last week (0408-0412)?
Weekly Report · 04/15 10:15
Weekly Report: what happened at CALA last week (0401-0405)?
Weekly Report · 04/08 10:18
Weekly Report: what happened at CALA last week (0325-0329)?
Weekly Report · 04/01 10:17
More
About CALA
Calithera Biosciences, Inc. is a clinical-stage, precision oncology biopharmaceutical company. The Company is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The Company is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The Company is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The Company's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.

Webull offers Calithera Biosciences Inc stock information, including EXMKT: CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.